Clinical studies with Paclitaxel - Eluting stent systems

Current Pharmaceutical Design

Volumn 16, Issue 36, 2010, Pages 4025-4036

  Bajaj, Neeraj R ^a   Garratt, Kirk N ^a  

^a LENOX HILL HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Clinical trials; Coronary artery disease; Drug eluting stent; Paclitaxel; Taxol

Indexed keywords

PACLITAXEL; POLYMER; RAPAMYCIN;

ANGIOPLASTY; ANTIANGIOGENIC ACTIVITY; ARTERY WALL; ARTICLE; BIODEGRADABLE IMPLANT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; CYTOSTASIS; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; HUMAN; IN-STENT RESTENOSIS; INTIMA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; HUMANS; PACLITAXEL; STENTS;

EID: 79952647313     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794454860     Document Type: Article

References (85)

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis Study Investigators. N Engl J Med 1994; 331(8): 496-501.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331(8): 489-95.
3. Cutlip D, Chauhan M, Baim D, et al. Clinical restenosis after coronary stenting; perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40(12): 2082-89.
4. FDA. 24 April 2003. FDA. 26 May 2010 . FDA. 4 March 2004.
5. FDA. 26 May 2010 .
6. Wani MC, Taylor HL, Wall ME, Coggan P, McPhail AT. Plant antitumoragents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-27.
7. Schiff PB, Fant J, Horwitz, SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277(5698): 665-7.
8. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-6.
9. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332: 1004-14.
10. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotuble agent. J Natl Cancer Inst 1990; 82: 1247-59.
11. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995; 95(4): 1869-76.
12. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-45.
13. Heldman AW, Cheng L, Heller P, et al. Paclitaxel applied directly to stents inhibits neointimal growth without thrombotic complications in a porcine coronary artery model of restenosis. Circulation 1997; 96: I-288.
14. Kornowski R, Hong MK, Ragheb AO, Bramwell O, Leon MB. Slow-release paclitaxel coated GRII stents reduce neointimal formation in a porcine coronary in-stent restenosis model. Circulation 1997; 96: I-341.
15. Farb A, Heller PF, Carter AJ, et al. Paclitaxel polymer-coated stents reduce neointima. Circulation 1997; 96: 1-608.
16. Heldman AW, Cheng L, Jenkins M, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289-95.
17. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104: 473-9.
18. Hong MK, Kornowski R, Bramwell O, et al. Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis 2001; 12: 513-5.
19. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000; 36: 2325-32.
20. Honda Y, Grube E, de la Fuente LM, et al. Novel drug delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001; 104: 380-3.
21. de la Fuente LM, Miano J, Mrad J, et al. Initial results of the Qua-nam drug eluting stent (QuaDS-QP-2) Registry (BARDDS) in human subjects. Catheter Cardiovasc Interv 2001; 53: 480-8.
22. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002; 105: 1883-6.
23. Grube E, Lansky A, Hauptman KE. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Car-diol 2004; 44: 1368-72.
24. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaluation of paclitaxel Eluting Stent (ELUTES) trial. Circulation 2004; 109: 487-93.
25. Swanson N, De Scheerder I, Chevalier B, et al. Two-year clinical results of a polymer-free, paclitaxel-eluting stent: the ELUTES trial. EuroIntervention 2007; 3: 109-12.
26. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348: 1537-45.
27. Park DW, Hong MK, Mintz GS, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late catch-up phenomenon from ASPECT Study. J Am Coll Cardiol 2006; 48:2432-9.
28. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based pacli-taxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004; 109:1948-54.
29. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.
30. Grube E, Silber S, Hauptmann KE, et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Amer J Cardiol 2005; 96: 79-82.
31. Bullesfeld L, Gerckens U, Muller R, Gurbe E. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I. Z Kardiol 2003; 92: 825-32.
32. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-94
33. Serruys PW, Degertekin M, Tanabe K, et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial in-travascular ultrasound analysis from the TAXUS II trial. Circulation 2004; 109: 627-33.
34. Silber S, Colombo A, Banning A, et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009; 120: 1498-504.
35. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
36. Weissman NJ, Koglin J, Cox DA, et al. Polymer-based paclitaxel-eluting stents reduce in-stent neointmal tissue proliferation: a serial volumetric intrascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1201-5
37. Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: treatment of de novo coronary disease using a single paclitaxel-eluting stent). J Am Coll Cardiol Intv 2009; 2: 1248-59
38. Stone GW, Ellis GW, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294: 1215-23.
39. Ellis SG, Cannon LA, Mann T, et al. Final five-year outcomes from the TAXUS V de novo trial: Long-term safety and effectiveness of the paclitaxel-eluting TAXUS stent in complex lesions. Am J Cardiol 2009; 104: 135D.
40. Turco MA, Ormiston JA, Popma JJ, et al. Polymer-based, pacli-taxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007; 49: 1676-83.
41. Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angi-ographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (prospective evaluation in a randomized trial of the safery and efficacy of the use of the TAXUS Element paclitaxel-eluting coronary stent system) trial. J Am Coll Cardiol 2010; 56 264-71.
42. Vranckx P, Serruys PW, Gambhir S, et al. Biodegradeable-polymer-based, paclitaxel-eluting Infinnium stent: 9-month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroIntervention 2006; 2: 310-7.
43. Krucoff MW, Kereiakes DJ, Petersen JL, et al. A novel bioresorb-able polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent with Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008; 51: 1543-52.
44. Unverdorben M, Degenhardt R, Wiemer M, et al. The paclitaxel-eluting Coroflex Please stent study (PECOPS I): the 3-year clinical follow-up. Catheter Cardiovasc Interv 2009; 74: 674-82.
45. Grube E, Schofer J, Hauptmann KE, et al. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradeable polymer: 9-month outcomes with the JACTAX HD stent. J Am Coll Cardiol Intv 2010; 3: 431-8.
46. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel-derivate eluting polymer stent system in humans. Circulation 2002; 106: 2649-51.
47. Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug eluting stents. N Eng J Med 2007; 356: 1020-9.
48. Brodie BR, Stuckey T, Downey W, et al. Outcomes and Complications With Off-Label Use of Drug-Eluting Stents: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group. J Am Coll Cardiol Intv 2008; 1: 405-14.
49. Lasala JM, Cox DA, Dobie D, et al. Usage Patterns and 2-Year Outcomes With the TAXUS Express Stent: Results of the US ARRIVE 1 Registry. Catheter Cardiovasc Interv 2008; 72: 433-45.
50. Lasala JM, Cox DA, Dobies D, et al. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv 2009; 2(4): 285-93.
51. Ahmed W, Zambahari R, Al-rashdan I, et al. One-Year Outcomes with the TAXUS Liberté Stent in the Real World: The TAXUS OLYMPIA Registry (Phase I). J of Interv Cardiol 2008; 21(6): 512-18.
52. Laarman G, Suttorp M, Dirksen M, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Eng J Med 2006; 355: 1105-13.
53. Vink, MA. Five-year clinical follow-up of the PASSION trial: Primary PCI with a paclitaxel-eluting stent vs. a bare-metal stent in acute ST-elevation myocardial infarction. American College of Cardiology Annual Scientific Session/i2 Summit. Atlanta, GA, 2010.
54. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360: 1946-59.
55. Stone GW. Data presented at: A prospective, multicenter randomized trial of heparin plus glycoprotein IIb/IIIa inhibitors vs. bivalirudin, and drug-eluting vs. bare metal stents in ST-segment elevation myocardial infarction: final report from the HORIZONS-AMI trial. TCT 2010. Washington DC. USA September 24, 2010.
56. Maehara A, Mintz GS, Lansky AJ, et al. Volumetric intravascular ultrasound analysis of paclitaxel-eluting and bare metal stents in acute myocardial infarction: the HORIZONS IVUS substudy. Circulation 2009; 120: 1875-82.
57. Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized controlled trial of paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions: the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009; 53: 919-28
58. Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007; 50: 261-7.
59. Mukherjee D, Moliterno DJ. Brachytherapy for in-stent restenosis: a distant second choice to drug-eluting stent placement. JAMA 2006; 295: 1307-9
60. Stone GW, Ellis SG, O'Shaughnessy C, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006; 295: 1253-63
61. Ellis SG, O'Shaughnessy C, Martin SL, et al. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. Eur Heart J 2008; 29: 1625-34.
62. Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008; 97: 773-81.
63. Holmes DR, Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis with bare-metal stents: the SISR randomized trial. JAMA 2006; 295: 1264-73.
64. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stents for the treatment of coronary in-stent restenosis. Circulation 2009; 119: 2986-94.
65. Stone GW, Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 2005; 112: 2530-37.
66. Buller CE, Dzavik V, Carere RG, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation 1999; 100: 236-42.
67. Rahel BM, Suttorp MJ, Laarman GJ, et al. Primary stenting of occluded native coronary arteries: Final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. Am Heart J 2004; 147: e22.
68. Kelbaek H, Helqvist S, Thuesen L, et al. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgoup analysis of the Stenting Coronary Arteries in Non-stress/Benestent Disease (SCANDSTENT) trial. Am Heart J 2006; 152: 882-6
69. Werner GS, Krack A, Schwarz G, et al. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol 2004; 44: 2301-6.
70. Thuesen L, Kelbaek H, Klovgaard L, et al. Comparison of si-rolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary arteries in Non-stress/Benestent Disease Trial (SCANDSTENT). Am Heart J 2006; 152: 1140-5.
71. Pan M, Suarez L, Medina A, et al. Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. Am Heart J 2007; 153(15): e1-7.
72. Song YB, Hahn J-Y, Choi S-H, et al. Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations: results from the COBIS (Coronary Bifurcation Stenting) registry. J Am Coll Cardiol 2010; 55: 1743-50.
73. Hoye A, Iakovou I, Ge L, et al. Long-term outcomes after stenting of bifurcation lesions with the crush technique: predictors of an adverse outcome. J Am Coll Cardio 2006; 47: 1949-58.
74. Kappetein AP. Data presented at: Optimal revascularization strategy in patients with three-vessel disease and/or left main disease: the 2-year outcomes of the SYNTAX trial. European Society of Cardiology Conference 2009. September 2, 2009; Barcelona, Spain.
75. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-72.
76. Erglis A, Narbute I, Kumsars I, et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 2007; 50: 491-97.
77. Kirtane AJ, Ellis SG, Dawkins KD, et al. Paclitaxel-eluting stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008; 51: 708-15.
78. Schomig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1373-80.
79. Stone GW. Data presented at: A large-scale randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical outcomes from the SPIRIT IV trial. TCT 2010. Washington DC. USA September 23, 2010.
80. Smits P. Data presented at: COMPARE trial: 2 year follow-up. TCT 2010. September 23, 2010: Washington DC, USA.
81. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010; 55: 543-54.
82. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007; 115: 2745-9.
83. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358: 689-99.
84. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005; 16: 331-8.
85. Dake M. Data presented at: The Zilver PTX Randomized Trial: 12-month Results of a Paclitaxel-Eluting Stent Versus Balloon Angioplasty and Bare Metal stenting in Patients with femoropopliteal Artery Disease. TCT 2010. Washington DC. USA September 24, 2010.